Escitalopram: A review of its use in the management of anxiety disorders

CNS Drugs

Volumn 20, Issue 9, 2006, Pages 763-790

  Dhillon, Sohita ^a   Scott, Lesley J ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CITALOPRAM; CLOMIPRAMINE; DEMETHYLCITALOPRAM; DESIPRAMINE; DIDEMETHYLCITALOPRAM; DRUG METABOLITE; ERYTHROMYCIN; ESCITALOPRAM; FLECAINIDE; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; METOPROLOL; NORTRIPTYLINE; OMEPRAZOLE; PAROXETINE; PROPAFENONE; RISPERIDONE; RITONAVIR; SEROPLEX; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SIPRALEXA; THIORIDAZINE; TICLOPIDINE; UNCLASSIFIED DRUG; VENLAFAXINE;

AGORAPHOBIA; ANORGASMIA; ANXIETY; ANXIETY DISORDER; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEMETHYLATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EJACULATION DISORDER; FATIGUE; GAIT DISORDER; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; INJURY; INSOMNIA; IRRITABILITY; LETHARGY; LIBIDO DISORDER; MENTAL STRESS; META ANALYSIS; MOOD DISORDER; MUSCLE TONE; NAUSEA; NERVOUSNESS; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RECURRENT DISEASE; REVIEW; SEROTONINERGIC NERVE CELL; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; SOMNOLENCE; STEADY STATE; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; SWEATING; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNPLEASANT DREAM; UPPER RESPIRATORY TRACT INFECTION; VIVID DREAM; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CITALOPRAM; HUMANS; MEDLINE;

EID: 33748606126     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620090-00010     Document Type: Review

References (86)

1. Thase ME. Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother 2006; 7 (4): 429-40
2. The WHO world mental health survey consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the world health organization world mental health surveys. JAMA 2004; 291 (21): 2581-90
3. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15 (4): 357-76
4. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19 (6): 567-96
5. Baldwin DS, Nair RV. Escitalopram in the treatment of generalized anxiety disorder. Expert Rev of Neurotherapeutics 2005; 5 (4): 443-9
6. Montgomery SA, Lecrubier Y, Baldwin DS, et al. ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder. Eur Neuropsychopharmacol 2004; 14 (5): 425-33
7. Culpepper L. Identifying and treating panic disorder in primary care. J Clin Psychiatry 2004; 65 Suppl 5: 19-23
8. Belzer K, Schneier FR. Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment. J Psychiatr Pract 2004; 10 (5): 296-306
9. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17 (5): 343-62
10. Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major deppressive disorder. Drugs 2005; 65 (16): 2379-404
11. Lundbeck AS. Cipralex European summary of product characteristics [online]. Available from URL: http:www.cipralex.com/images/Cipralex/smpc.pdf [Accessed 2005 Jul 17]
12. Sanchez C, Bergqvist PB, Brennum LT, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003; 167 (4): 353-62
13. Rausch JL, Corley KM, Hobby HM. Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique. J Clin Psychopharmacol 2004; 24 (2): 209-13
14. Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003; 45 (2): 167-73
15. Chen F, Larsen MB, Sanchez C, et al. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism: comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005; 15 (2): 193-8
16. Forest Laboratories Inc. Lexapro (escitalopram oxalate): US prescribing information [online]. Available from URL: http://www.lexapro.com [Accessed 2006 Mar 21]
17. El Mansari M, Sanchez C, Chouvet G, et al. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in the rat brain. Neuropsychopharmacology 2005; 30: 1269-77
18. Thomsen C, Helboe L. Regional pattern of binding and c-Fos induction by (R)- and (S)-citalopram in rat brain. Neuroreport 2003; 14: 2411-4
19. Uys JD, Muller CJ, Marais L, et al. Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: reversal by escitalopram. Neuroscience 2006; 137 (2): 619-25
20. Jayatissa MN, Bisgaard C, Tingstorm A, et al. Hippocampal cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of depression. Neuropsychopharmacology 2006; [Epub ahead of print, doi:10.1038/sj.npp.1301041]
21. Fish EW, Faccidomo S, Gupta S, et al. Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups. J Pharmacol Exp Ther 2004; 308 (2): 474-80
22. Sanchez C, Gruca P, Bien E, et al. R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav 2003; 75 (4): 903-7
23. Sanchez C. R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur J Pharmacol 2003; 464 (2-3): 155-8
24. Mitchell PJ, Hogg S, Sanchez C. The effects of acute and chronic treatment with S(+)- and R(-)-citalopram, given alone and in combination, on the agonistic behaviour of resident rats. Biol Psychiatry 2004; 55 Suppl. 8: 120S
25. Klein N, Sacher J, Geiss-Granadia T, et al. Multiple dose administration of escitalopram resulted in a higher serotonin transporter occupancy than citalopram: a [I123]ADAM SPECT study in healthy volunteers [abstract No. 804]. Biol Psychiatry 2006; 59 Suppl. 1: 246S
26. Nadeem HS, Attenburrow MJ, Cowen PJ. Comparison of the effects of citalopram and escitalopram on 5-HT-mediated neuroendocrine responses. Neuropsychopharmacology 2004; 29 (9): 1699-703
27. Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005; 66 (4): 436-43
28. Lundbeck Canada Inc. Annotated prescribing information: escitalopram. Montreal (QC): Lundbeck Canada Inc, 2005
29. Sanchez C, Bogeso KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004; 174 (2): 163-76
30. Sanchez C, Gruca P, Papp M. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 2003; 14 (5-6): 465-70
31. Storustovu S, Sanchez C, Porzgen P, et al. R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 2004; 142 (1): 172-80
32. Mnie-Filali O, Mansari ME, Espana A, et al. Allosteric modulation of the effects of the 5-HT reuptake inhibitor escitalopram on the rat hippocampal synaptic plasticity. Neurosci Lett 2006; 395: 23-7
33. Sanchez C, Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 2004; 77 (2): 391-8
34. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50: 345-50
35. Ceglia I, Acconcia S, Fracasso C, et al. Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors. Br J Pharmacol 2004; 142 (3): 469-78
36. Søgaard B, Mengel H, Rao N, et al. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 2005; 45: 1-7
37. Rampono J, Hackett LP, Kristensen JH, et al. Transfer of escitalopram and its metabolite demethylescitalopram into breast milk. Br J Clin Pharmacol 2006; [Epub ahead of print, doi: 10.1111/j.1365-2125.2006.02659.x]
38. Rampono J, Kristensen JH, Hackett LP, et al. Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol 2000; 50: 263-8
39. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29 (8): 1102-9
40. Olesen OV, Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 1999; 59 (6): 298-309
41. Areberg J, Christophersen JS, Poulsen MN, et al. Pharmacokinetics of escitalopram in subjects with hepatic impairment. AAPS J 2006; 8 (1): E14-9
42. Malling D, Poulsen MN, Søgaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol 2005; 60 (3): 287-90
43. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003; 25 (4): 1200-10
44. Preskorn SH, Klick-Davis A, Coyner L, et al. The effect of escitalopram versus setraline versus duloxetine on CYP 2D6 function [abstract no. NR877 plus poster]. New research abstracts. American Psychiatric Association Annual Meeting; 2005 May 21-26; Atlanta (GA):, 326-7
45. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17 (2): 65-9
46. Lader M, Stender K, Burger V, et al. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004; 19 (4): 241-8
47. Stein DJ, Andersen EW, Lader M. Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions. Eur Neuropsychopharmacol 2006; 16: 33-8
48. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003; 64 (11): 1322-7
49. Davidson JRT, Bose A, Korotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004; 19 (4): 234-40
50. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005; 87 (2-3): 161-7
51. Allgulander C, Florea I, Huusom AKT. Prevention of relapse in generalised anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2005; [Epub ahead of print, doi:10.1017/S1461145705005973]
52. Stein DJ, Andersen HF, Goodman WK. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry 2005; 17 (2): 71-5
53. Kasper S, Stein DJ, Loft H, et al. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005; 186: 222-6
54. Montgomery SA, Nil R, Durr-Pal N, et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66 (10): 1270-8
55. Davidson JR, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2005; 66 (11): 1441-6
56. Rampello L, Alvano A, Raffaele R, et al. New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. J Clin Psychopharmacol 2006; 26 (1): 67-70
57. Forest Laboratories. Data on file [online]. Available from URL: www.forestclinicaltrials.com [Accessed 2006 Jul 6]
58. Davidson J, Bose A, Su G. Escitalopram in the treatment of generalized anxiety disorder [abstract no. P.4.W.059]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: S214. Plus poster presented at the 23rd Psychopharmacolgicum; 2002 June 23-27; Montreal (QC)
59. Stein DJ, Tonnoir B, Andersen EW. Escitalopram in the treatment of OCD [abstract no. NR717 plus poster]. American Psychiatric Association Annual Meeting; 2006 May 20-25; Toronto (ON)
60. Baldwin DS, Huusom AKR, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 2006; 189 (3): 264-72
61. Fineberg N, Lemming O, Tonnoir B. Escitalopram in relapse prevention in patients with OCD [abstract no. NR504 plus poster]. American Psychiatric Association 2006 Annual Meeting; 2006 May 20-25; Toronto (ON)
62. Schneier FR, Blanco C, Campeas R, et al. Escitalopram treatment of social anxiety disorder with comorbid major depression [abstract no. 69]. Neuropsychopharmacology 2004; 29 Suppl. 1: 206
63. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC. American Psychiatric Association, 1994
64. Jorgensen TR, Despiegel N, Francois C. Escitalopram treatment improves quality of life of generalised anxiety disorder patients measured by SF-36 [abstract no. P-330/1448 plus poster]. Qual Life Res 2005; 14 (9): 2146. Plus poster presented at the 12th Annual Conference of the International Society for Quality of Life Research; 2005 October 19-12; San Francisco (CA)
65. Data on file, Lundbeck, 2006
66. Baldwin DS, Montgomery SA, Nil R, et al. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 2005, [Epub ahead of print, doi:10.1017/S1461145705006358]
67. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review [online]. BMJ 2005; 330 (7488): 385. Available from URL: http://bmj.bmj- journals.com [Accessed 2006 Jul 1]
68. Pedersen AG. Escitalopram and suicidality in adult depression and anxiety. Int Clin Psychopharmacol 2005; 20 (3): 139-43
69. Wagner KD, Jonas J, Findling R, et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad of Child and Adolosc Psychiatry 2006; 45 (3): 280-8
70. Lovecchio F, Watts D, Winchell J, et al. Outcomes after supratherapeutic escitalopram ingestions. J Emerg Med 2006; 30 (1): 17-9
71. Seifert SA, Meissner GK. Escitalopram overdose: a case series [abstract no. 121]. J Toxicol Clin Toxicol 2004; 42: 495-6
72. Olsen D, Dart R, Robinett M. Severe serotonin syndrome from escitalopram overdose [abstract no. 72]. J Toxicol Clin Toxicol 2004; 42: 744-5
73. Lundbeck A/S. Lundbeck files application for approval of Cipralex® for the treatment of obsessive-compulsive disorder (OCD) [online]. Available from URL: http://www.lundbeck.com [Accessed 2006 May 3]
74. Valuck R. Selective serotonin reuptake inhibitors: a class review. PT 2004; 29 (4): 234-43
75. Lele M, Joglekar A. Escitalopram for social anxiety disorder [letter]. Br J Psychiatry 2005 Sep; 187: 290-1
76. Kasper S, Stein D, Loft H. Authors reply to correspondence by Lele and Joglekar [letter]. Br J Psychiatry 2005; 187: 291-2
77. Olié JP, Menard F, Galinowski A, et al. Escitalopram efficacy in depressed patients with comorbid anxiety [abstract no. PO-021.13]. World J Biol Psych 2005; 6 Suppl. 1: 283
78. Boulenger JP, Huusom AK, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006; 22 (7): 1331-41
79. Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Biol Psychiatry 2004; 50: 57-64
80. Bielski RJ, Ventura D, Chang C. A double-blind comparison of escitalopram and velafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65 (9): 1190-6
81. Montgomery SA, Anderson FH. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006; 21: 297-309
82. GlaxoSmithKline. Paxil (paroxetine hydrochloride): US prescribing information [online]. Available from URL: http://www.fda.gov [Accessed 2006 Apr 28]
83. Sheehan DV, Eaddy MT, Shah MB, et al. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. Am J Manag Care 2005; 11 Suppl. 12: S354-61
84. Parker G, Tully L, Olley A, et al. SSRIs as mood stabilizers for bipolar II disorder? A proof of concept study. J Affect Disord 2006; 92: 205-14
85. Fonseca M, Soares JC, Hatch JP, et al. An open trial of adjunctive escitalopram in bipolar depression. J Clin Psychiatry 2006; 67 (1): 81-6
86. Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol 2006; 21 (3): 177-9